Skip to main content
OpenTrials
Completed

NCT Number: NCT00488267

Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee

ThermoProfen is a transdermal ketoprofen patch that is integrated with a long-lasting CHADD (Controlled Heat-Assisted Drug Delivery) unit for the treatment of chronic pain associated with osteoarthritis. This study will evaluate ThermoProfen for the treatment of mild to moderate pain associated with osteoarthritis of the knee in adults.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Peoria, Arizona, United States

Loading trial locations.

About this study

The primary objective of the study is to compare the efficacy of ThermoProfen™ against two other experimental treatments.

The treatment may be ThermoProfen (Matrix Transdermal Ketoprofen Patch) or a patch that may or may not include ketoprofen and that may or may not provide heat.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is 18 through 75 years of age
  • Patient has radiographic evidence of osteoarthritis of the target knee obtained within the past year.

Exclusion criteria

  • Patient has a known allergy to nonsteroidal anti-inflammatory drugs (NSAIDs, including aspirin).
  • Patient has asthma that has been induced or made worse by the use of aspirin or NSAIDs.
  • Patient has a relevant history of serious gastrointestinal disease.
  • Patient, if female, is pregnant or breastfeeding or is of childbearing potential and not practicing adequate birth control.
  • Patient is taking warfarin, heparin, or low molecular weight heparin.
  • Patient has received oral, intramuscular, intravenous, intra-articular, or soft-tissue administration of steroids within 1 month of study enrollment (or within 2 months, if in the target joint).
  • Patient has received intra-articular visco-supplementation (in target joint) within 6 months of study enrollment.

Treatment and study plan

ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)

Drug

Transdermal patch applied to the knee for 12 hours daily.

Other names: Matrix Transdermal Ketoprofen CHADD System

Placebo Matrix/CHADD Patch

Drug

Transdermal patch applied to the knee for 12 hours daily.

Other names: Placebo patch with heating system

Ketoprofen matrix/placebo CHADD Patch

Drug

Transdermal knee applied to the knee for 12 hours daily.

Other names: ketoprofen matrix with no heat

Primary outcomes

  1. The primary outcome measure is the change from baseline in the Visual Analog Scale score for the average pain during the previous 24 hours.

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline in Visual Analog Scale score for worst pain during the previous 24 hours, amount of rescue medication used to treat the target joint per day, and the patient global impression of change in the Likert Scale

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

ZARS Pharma Inc.

Industry

Registry information

Official study title

A Randomized, Double-Blind, 12-Week Study to Evaluate the Efficacy of ThermoProfen™ in the Treatment of Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee (ZMK-301)

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Jun 20, 2007
Registry last updated
May 30, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.